Previous 10 | Next 10 |
home / stock / bmymp / bmymp news
Bristol-Myers Squibb Company (BMY) Morgan Stanley 19th Annual Global Healthcare Conference September 14, 2021, 08:00 AM ET Company Participants Giovanni Caforio - Chairman & CEO Conference Call Participants Matthew Harrison - Morgan Stanley Presentation Matthew Harrison Good morning, ever...
Quietly, there has been a historical capital rotation that has been ongoing in the markets for roughly a year-and-a-half now. Economically-sensitive and inflationary-sensitive stocks are significantly outperforming over this time frame. This outperformance can get lost in the back...
My monthly review of DivGro provides a summary of transactions and explains how those transactions affect projected annual dividend income. DivGro is my portfolio of dividend growth stocks. In August, I opened two new positions and added shares to three existing positions. DivGro now ...
The Wall Street Analyst consensus on BMY is overwhelmingly bullish. Seeking Alpha authors are bullish on BMY as well. However, the Seeking Alpha Quant rating system gives a neutral outlook on BMY. We explain why we side with the Quant rating system over Wall Street and Seeking...
We explain why selling the cash-covered puts and covered calls are safer choices and earn income. We will discuss how to formulate an options income strategy that's sustainable and repeatable. In this periodic series, we present how to go about selecting the right kind of stocks f...
Some estimates show that BMY has as much as 100% upside at fair prices. After digging into this stock - I'm not so sure about that story. BMY is a great business with great returns on capital - but it only offers a small upside today. It's undervalued, but not by much. For f...
Berkshire Hathaway's 13F stock portfolio value increased from $270.44B to $293.02B this quarter. Their largest three holdings are at ~64% of the entire portfolio. Berkshire Hathaway increased Kroger while reducing Merck and Liberty Global during the quarter. For further deta...
Incyte Corp is a biopharmaceutical company conducting both commercial and clinical development operations. According to the most recent quarterly report, Incyte Corporation appears to see that growth is returning to pre-covid levels. In 2025, if the FDA does not approve many more ...
Horizon Therapeutics has now reached a growth point that is supportive of long-term success due to multiple eggs in the basket. The company has 11 FDA approved drugs and 10 phase 2 or 3 clinical trials underway, with revenue growth currently averaging 91% per year over the past 10 yea...
A monthly income stream provides a lot of flexibility for the income investor. Monthly dividends makes DCA work even better. Three picks with reliable monthly dividends. For further details see: 3 Big Dividends, Paying Monthly, For Your Retirement Basea
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb $2Pr Company Name:
BMYMP Stock Symbol:
OTCMKTS Market:
Bristol-Myers Squibb $2Pr Website: